M
Minoru Takada
Researcher at Kindai University
Publications - 162
Citations - 10908
Minoru Takada is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 39, co-authored 158 publications receiving 10248 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
Journal ArticleDOI
Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104
Minoru Takada,Masahiro Fukuoka,Masaaki Kawahara,Takahiko Sugiura,A. Yokoyama,Soichiro Yokota,Yutaka Nishiwaki,Koshiro Watanabe,Kazumasa Noda,Tomohide Tamura,Haruhiko Fukuda,Nagahiro Saijo +11 more
TL;DR: This study strongly suggests that cisplatin plus etoposide and concurrent radiotherapy is more effective for the treatment of LS-SCLC than cisPlatin plus Etoposid and sequential radiotherapy.
Journal ArticleDOI
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka,Kreshnik Zejnullahu,Isamu Okamoto,Taroh Satoh,Federico Cappuzzo,John Souglakos,Dalia Ercan,Andrew H. Rogers,Massimo Roncalli,Masayuki Takeda,Yasuhito Fujisaka,Juliet Philips,Toshio Shimizu,Osamu Maenishi,Yonggon Cho,Jason Sun,Annarita Destro,Koichi Taira,Koji Takeda,Takafumi Okabe,Jeffrey Swanson,Hiroyuki Itoh,Minoru Takada,Eugene Lifshits,Kiyotaka Okuno,Jeffrey A. Engelman,Ramesh A. Shivdasani,Ramesh A. Shivdasani,Kazuto Nishio,Masahiro Fukuoka,Marileila Varella-Garcia,Kazuhiko Nakagawa,Pasi A. Jänne,Pasi A. Jänne +33 more
TL;DR: Examination of cellular data with patient experience improves confidence that concomitant treatment of certain lung, head and neck, or colorectal cancers with cetuximab and an anti-ERBB2 drug may prevent or delay the development of drug resistance.
Journal ArticleDOI
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
Noriyuki Masuda,Masahiro Fukuoka,Yoko Kusunoki,Kaoru Matsui,Nobuhide Takifuji,Shinzoh Kudoh,Shunichi Negoro,Masayuki Nishioka,Kazuhiko Nakagawa,Minoru Takada +9 more
TL;DR: CPT-11 is an active agent against refractory or relapsed SCLC and deserves to be studied more closely as both a single agent and in combination with other drugs to treat patients with SclC.
Journal ArticleDOI
Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
Shinzoh Kudoh,Koji Takeda,Kazuhiko Nakagawa,Minoru Takada,Nobuyuki Katakami,Kaoru Matsui,Tetsu Shinkai,Toshiyuki Sawa,Isao Goto,Hiroshi Semba,Takashi Seto,Masahiko Ando,Taroh Satoh,Naruo Yoshimura,Shunichi Negoro,Masahiro Fukuoka +15 more
TL;DR: Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine, and may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.